Confluence Genetics Launches Cas-CLEAR CRISPR Platform for Cancer Treatment
Confluence Genetics announced the launch of Cas-CLEAR, short for Collaterally Enhanced Activated Ribonuclease, a CRISPR-based platform built to treat cancers carrying defined genetic signatures. The company's lead programs target hepatocellular carcinoma (HCC), a leading cause of cancer death worldwide with limited options for advanced disease.